Nature Biotechnology · 7 September 2026 · From issue 33
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
Six blood-based aging tests agreed a lung drug trial lowered patients' biological age.
Alex Zhavoronkov, Fedor Galkin et al.
A drug being tested for a lung scarring disease also made patients' blood look biologically younger. Six different tools that measure biological age from blood proteins all agreed on this after just 12 weeks of treatment. The tools could not fully tell apart aging effects from disease effects. So scientists checked cell pathways instead, and found hints of anti-aging changes alongside the drug's known anti-scarring effect.
All six blood protein aging tests showed lower biological age in treated patients after 12 weeks.
One 12-week trial, disease and aging effects not fully separated.
Integrity screen: passed (3 checks) Checked 6 October 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Biotechnology). Read the source
This screen checks process signals. It does not tell you the findings are true.